Agazisiran Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Agazisiran Growth

• Novel RNAi mechanism targeting ANGPTL3 for cardiometabolic diseases

Agazisiran is a GalNAc-conjugated small interfering RNA (siRNA) designed to selectively silence hepatic ANGPTL3 expression. ANGPTL3 is a validated regulator of triglycerides, LDL cholesterol, and other atherogenic lipoproteins. Human genetic studies have shown that individuals with loss-of-function ANGPTL3 variants have significantly lower lipid levels and reduced risk of atherosclerotic cardiovascular disease, providing strong biological validation for this therapeutic target.

• Potential for infrequent dosing and improved patient adherence

Like other GalNAc-siRNA therapeutics, Agazisiran is designed for targeted uptake by hepatocytes, enabling prolonged suppression of the target protein after a single administration. Long-acting RNAi therapies have demonstrated the ability to maintain pharmacodynamic effects for several months, potentially allowing dosing only two to four times annually. Such a dosing schedule could improve adherence compared with daily oral lipid-lowering therapies and provide a competitive advantage if clinical efficacy is confirmed. The success of other liver-directed RNAi agents has validated this development strategy.

• Large addressable market in dyslipidemia and cardiovascular disease

Elevated triglycerides and residual cardiovascular risk remain substantial unmet medical needs despite widespread statin use. Therapies targeting ANGPTL3 may benefit patients with mixed dyslipidemia, severe hypertriglyceridemia, familial lipid disorders, and patients who remain at high cardiovascular risk despite standard lipid-lowering treatment. This broad potential patient population supports significant long-term commercial opportunity if efficacy and safety are demonstrated in clinical trials.

• Validated therapeutic target reduces scientific risk

ANGPTL3 has already been clinically validated through both human genetics and approved therapeutic approaches, demonstrating that lowering ANGPTL3 improves lipid parameters. Agazisiran benefits from targeting a well-established pathway while utilizing an RNAi modality capable of sustained gene silencing, potentially offering durable lipid lowering with fewer administrations than antibody-based therapies.

• Expanding acceptance of RNAi therapeutics

Regulatory approvals of multiple GalNAc-conjugated siRNA medicines over recent years have established RNA interference as a clinically validated platform. Growing physician familiarity, scalable manufacturing capabilities, and increasing confidence among regulators reduce platform-related development risk for newer RNAi candidates such as Agazisiran and may facilitate future commercialization if clinical endpoints are successfully achieved.  

Agazisiran Recent Developments

In November 2025, ADARx released efficacy and AE data from the Phase I PNH trial of Agazisiran, summarizing trial outcomes and marking a key readout milestone for the program; this is noted in drug pipeline databases as a “most recent event”.

In May 2025, ADARx publicized its plans for Phase II trials of Agazisiran in membranous glomerulonephritis/IgA nephropathy and dry AMD, including indicative timelines (July-August 2025) and trial IDs, effectively serving as a forward looking press communication to the clinical and investor communities.

“Agazisiran Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Agazisiran for potential indication like Dry age-related macular degeneration, IgA nephropathy, Membranoproliferative glomerulonephritis, and Paroxysmal nocturnal haemoglobinuria in the 7MM. A detailed picture of Agazisiran’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Agazisiran for potential indications. The Agazisiran market report provides insights about Agazisiran’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Agazisiran performance, future market assessments inclusive of the Agazisiran market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Agazisiran sales forecasts, along with factors driving its market.

Agazisiran Drug Summary

Agazisiran (formerly AZD2693) is an investigational RNA interference (RNAi) therapeutic developed by AstraZeneca for the treatment of transthyretin (ATTR) amyloidosis. It is a subcutaneously administered small interfering RNA (siRNA) designed to selectively silence the TTR gene in hepatocytes, thereby reducing the production of both mutant and wild-type transthyretin protein that forms pathogenic amyloid deposits in peripheral nerves, the heart, and other tissues. Utilizing a liver-targeting delivery technology, agazisiran aims to achieve durable suppression of circulating transthyretin levels with infrequent dosing, potentially slowing disease progression and improving clinical outcomes in patients with hereditary and wild-type ATTR amyloidosis. Preclinical studies demonstrated potent and sustained TTR knockdown with a favorable safety profile, supporting its advancement into early clinical development. Agazisiran is being evaluated in Phase I studies to characterize its safety, pharmacokinetics, pharmacodynamics, and degree of serum TTR reduction as a next-generation gene-silencing therapy for ATTR amyloidosis. The report provides Agazisiran’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Agazisiran Market Report

The report provides insights into:

• A comprehensive product overview including the Agazisiran MoA, description, dosage and administration, research and development activities in potential indication like Dry age-related macular degeneration, IgA nephropathy, Membranoproliferative glomerulonephritis, and Paroxysmal nocturnal haemoglobinuria.
• Elaborated details on Agazisiran regulatory milestones and other development activities have been provided in Agazisiran market report.
• The report also highlights Agazisiran‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Agazisiran market report also covers the patents information, generic entry and impact on cost cut.
• The Agazisiran market report contains current and forecasted Agazisiran sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Agazisiran market report also features the SWOT analysis with analyst views for Agazisiran in potential indications.

Methodology

The Agazisiran market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Agazisiran Analytical Perspective

• In-depth Agazisiran Market Assessment

This Agazisiran sales market forecast report provides a detailed market assessment of Agazisiran for potential indication like Dry age-related macular degeneration, IgA nephropathy, Membranoproliferative glomerulonephritis, and Paroxysmal nocturnal haemoglobinuria in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Agazisiran sales data uptil 2034.

• Agazisiran Clinical Assessment

The Agazisiran market report provides the clinical trials information of Agazisiran for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Agazisiran Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Agazisiran Market Potential & Revenue Forecast

• Projected market size for the Agazisiran and its key indications
• Estimated Agazisiran sales potential (Agazisiran peak sales forecasts)
• Agazisiran Pricing strategies and reimbursement landscape

Agazisiran Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Agazisiran Market positioning compared to existing treatments
• Agazisiran Strengths & weaknesses relative to competitors

Agazisiran Regulatory & Commercial Milestones

• Agazisiran Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Agazisiran Clinical Differentiation

• Agazisiran Efficacy & safety advantages over existing drugs
• Agazisiran Unique selling points

Agazisiran Market Report Highlights

• In the coming years, the Agazisiran market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Agazisiran companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Agazisiran’s dominance.
• Other emerging products for Dry age-related macular degeneration, IgA nephropathy, Membranoproliferative glomerulonephritis, and Paroxysmal nocturnal haemoglobinuria are expected to give tough market competition to Agazisiran and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Agazisiran in potential indications.
• Analyse Agazisiran cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Agazisiran sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Agazisiran in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Agazisiran? How strong is Agazisiran’s clinical and commercial performance?
• What is Agazisiran’s clinical trial status in each individual indications such as Dry age-related macular degeneration, IgA nephropathy, Membranoproliferative glomerulonephritis, and Paroxysmal nocturnal haemoglobinuria and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Agazisiran Manufacturers?
• What are the key designations that have been granted to Agazisiran for potential indications? How are they going to impact Agazisiran’s penetration in various geographies?
• What is the current and forecasted Agazisiran market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Agazisiran in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Agazisiran for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Agazisiran? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.